NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells
Authors:
Open Access
- 17 February 2021
- journal article
- research article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 27, 100340
Abstract
No abstract availableKeywords
Funding Information
- NIFA
- NSF
- NIFA
- NIGMS
- HHMI
- NSF
This publication has 103 references indexed in Scilit:
- Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cellsCellular Signalling, 2013
- Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemiaMolecular Cancer, 2013
- Targeting the PI3K signaling pathway in cancerCurrent Opinion in Genetics & Development, 2010
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsProceedings of the National Academy of Sciences, 2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumorsNature Genetics, 2008
- Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repairNature Genetics, 2007
- Basal-like breast cancer and the BRCA1 phenotypeOncogene, 2006
- Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesisOncogene, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001